Dataset from A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor (bPI) Combined With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in Virologically-suppressed, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects

The purpose of this study is to demonstrate non-inferiority in efficacy while switching to a
once-daily single-tablet regimen containing darunavir (DRV)/ cobicistat (COBI)/ emtricitabine
(FTC)/ tenofovir alafenamide (TAF) (D/C/F/TAF tablet) relative to continuing the current
regimen consisting of a boosted protease inhibitor (bPI) combined with tenofovir disoproxil
fumarate (FTC/TDF) in virologically-suppressed (human immunodeficiency virus type 1
ribonucleic acid [HIV-1 RNA] concentrations less than [<] 50 copies per milliliter
[copies/mL]) HIV-1 infected participants.